Targeting Schlemm’s Canal in the Medical Therapy of Glaucoma: Current and Future Considerations

Advances in Therapy - Tập 34 - Trang 1049-1069 - 2017
Vanessa Andrés-Guerrero1,2, Julián García-Feijoo1,3,2, Anastasios Georgios Konstas4
1Department of Ophthalmology, Sanitary Research Institute of the San Carlos Clinical Hospital, Madrid, Spain
2Ocular Pathology National Net OftaRed of the Institute of Health Carlos III, Madrid, Spain
3Department of Ophthalmology, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain
41st and 3rd University Departments of Ophthalmology, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Tóm tắt

Schlemm’s canal (SC) is a unique, complex vascular structure responsible for maintaining fluid homeostasis within the anterior segment of the eye by draining the excess of aqueous humour. In glaucoma, a heterogeneous group of eye disorders afflicting approximately 60 million individuals worldwide, the normal outflow of aqueous humour into SC is progressively hindered, leading to a gradual increase in outflow resistance, which gradually results in elevated intraocular pressure (IOP). By and large available antiglaucoma therapies do not target the site of the pathology (SC), but rather aim to decrease IOP by other mechanisms, either reducing aqueous production or by diverting aqueous flow through the unconventional outflow system. The present review first outlines our current understanding on the functional anatomy of SC. It then summarizes existing research on SC cell properties; first in the context of their role in glaucoma development/progression and then as a target of novel and emerging antiglaucoma therapies. Evidence from ongoing research efforts to develop effective antiglaucoma therapies targeting SC suggests that this could become a promising site of future therapeutic interventions.

Tài liệu tham khảo

Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–7.

De Groef L, Van Hove I, Dekeyster E, Stalmans I, Moons L. MMPs in the trabecular meshwork: promising targets for future glaucoma therapies? Invest Ophthalmol Vis Sci. 2013;54(12):7756–63.

Lütjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp Eye Res. 2005;81(1):1–4.

Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–11.

Brubaker RF. Flow of aqueous humor in humans [The Friedenwald Lecture]. Invest Ophthalmol Vis Sci. 1991;32(13):3145–66.

Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4:52–9.

Mark HH. Aqueous humor dynamics in historical perspective. Surv Ophthalmol. 2010;55(1):89–100.

Civan MM, Macknight AD. The ins and outs of aqueous humour secretion. Exp Eye Res. 2004;78(3):625–31.

Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res. 2009;88(4):648–55.

Agarwal S. Textbook of ophthalmology: New Delhi; 2002.

Hann CR, Vercnocke AJ, Bentley MD, Jorgensen SM, Fautsch MP. Anatomic changes in Schlemm’s canal and collector channels in normal and primary open-angle glaucoma eyes using low and high perfusion pressures. Invest Ophthalmol Vis Sci. 2014;55(9):5834–41.

Stamer WD, Braakman ST, Zhou EH, Ethier CR, Fredberg JJ, Overby DR, et al. Biomechanics of Schlemm’s canal endothelium and intraocular pressure reduction. Prog Retin Eye Res. 2015;44:86–98.

Lütjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog Retin Eye Res. 1999;18(1):91–119.

Herrnberger L, Ebner K, Junglas B, Tamm ER. The role of plasmalemma vesicle-associated protein (PLVAP) in endothelial cells of Schlemm’s canal and ocular capillaries. Exp Eye Res. 2012;105:27–33.

Johnson M. What controls aqueous humour outflow resistance? Exp Eye Res. 2006;82(4):545–57.

Bill A, Mäepea O. Mechanisms and routes of aqueous humor drainage. Principles and practice of ophthalmology. Albert DM, Jakobiec FA (eds.). St Louis: Saunders; 1995.

Johnson M, Shapiro A, Ethier CR, Kamm RD. Modulation of outflow resistance by the pores of the inner wall endothelium. Invest Ophthalmol Vis Sci. 1992;33(5):1670–5.

Allingham RR, de Kater AW, Ethier CR, Anderson PJ, Hertzmark E, Epstein DL. The relationship between pore density and outflow facility in human eyes. Invest Ophthalmol Vis Sci. 1992;33(5):1661–9.

Johnson M, Chan D, Read AT, Christensen C, Sit A, Ethier CR. The pore density in the inner wall endothelium of Schlemm’s canal of glaucomatous eyes. Invest Ophthalmol Vis Sci. 2002;43(9):2950–5.

Sit AJ, Coloma FM, Ethier CR, Johnson M. Factors affecting the pores of the inner wall endothelium of Schlemm’s canal. Invest Ophthalmol Vis Sci. 1997;38(8):1517–25.

Braakman ST, Read AT, Chan DW, Ethier CR, Overby DR. Colocalization of outflow segmentation and pores along the inner wall of Schlemm’s canal. Exp Eye Res. 2015;130:87–96.

Overby DR, Zhou EH, Vargas-Pinto R, Pedrigi RM, Fuchshofer R, Braakman ST, et al. Altered mechanobiology of Schlemm’s canal endothelial cells in glaucoma. Proc Natl Acad Sci USA. 2014;111(38):13876–81.

Peterson JA, Tian B, Bershadsky AD, Volberg T, Gangnon RE, Spector I, et al. Latrunculin-A increases outflow facility in the monkey. Invest Ophthalmol Vis Sci. 1999;40(5):931–41.

Sabanay I, Tian B, Gabelt BT, Geiger B, Kaufman PL. Functional and structural reversibility of H-7 effects on the conventional aqueous outflow pathway in monkeys. Exp Eye Res. 2004;78(1):137–50.

Ethier CR, Read AT, Chan DW. Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest Ophthalmol Vis Sci. 2006;47(5):1991–8.

Sabanay I, Tian B, Gabelt BT, Geiger B, Kaufman PL. Latrunculin B effects on trabecular meshwork and corneal endothelial morphology in monkeys. Exp Eye Res. 2006;82(2):236–46.

Rao VP, Epstein DL. Rho GTPase/Rho Kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007;21(3):167–77.

Yücel YH, Johnston MG, Ly T, Patel M, Drake B, Gümüş E, et al. Identification of lymphatics in the ciliary body of the human eye: a novel “uveolymphatic” outflow pathway. Exp Eye Res. 2009;89(5):810–9.

Birke K, Lütjen-Drecoll E, Kerjaschki D, Birke MT. Expression of podoplanin and other lymphatic markers in the human anterior eye segment. Invest Ophthalmol Vis Sci. 2010;51(1):344–54.

Hoopes SL, Willcockson HH, Caron KM. Characteristics of multi-organ lymphangiectasia resulting from temporal deletion of calcitonin receptor-like receptor in adult mice. PLoS ONE. 2012;7(9):e45261.

Truong TN, Li H, Hong YK, Chen L. Novel characterization and live imaging of Schlemm’s canal expressing Prox-1. PLoS ONE. 2014;9(5):e98245.

Overby DR, Stamer WD, Johnson M. The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res. 2009;88(4):656–70.

Junglas B, Kuespert S, Seleem AA, Struller T, Ullmann S, Bösl M, et al. Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork. Am J Pathol. 2012;180(6):2386–403.

Tian B, Kaufman PL. Comparisons of actin filament disruptors and Rho Kinase inhibitors as potential antiglaucoma medications. Expert Rev Ophthalmol. 2012;7(2):177–87.

Zhou EH, Krishnan R, Stamer WD, Perkumas KM, Rajendran K, Nabhan JF, et al. Mechanical responsiveness of the endothelial cell of Schlemm’s canal: scope, variability and its potential role in controlling aqueous humour outflow. J R Soc Interface. 2012;9(71):1144–55.

Keller KE, Acott TS. The Juxtacanalicular region of ocular trabecular meshwork: a tissue with a unique extracellular matrix and specialized function. J Ocul Biol. 2013;1(1):3.

Swaminathan SS, Oh DJ, Kang MH, Ren R, Jin R, Gong H, et al. Secreted protein acidic and rich in cysteine (SPARC)-null mice exhibit more uniform outflow. Invest Ophthalmol Vis Sci. 2013;54(3):2035–47.

Camras LJ, Stamer WD, Epstein D, Gonzalez P, Yuan F. Circumferential tensile stiffness of glaucomatous trabecular meshwork. Invest Ophthalmol Vis Sci. 2014;55(2):814–23.

Crosson CE, Gray T. Modulation of intraocular pressure by adenosine agonists. J Ocul Pharmacol. 1994;10(1):379–83.

Crosson CE. Adenosine receptor activation modulates intraocular pressure in rabbits. J Pharmacol Exp Ther. 1995;273(1):320–6.

Tian B, Gabelt BT, Crosson CE, Kaufman PL. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res. 1997;64(6):979–89.

Avila MY, Stone RA, Civan MM. A(1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse. Br J Pharmacol. 2001;134(2):241–5.

Crosson CE. Intraocular pressure responses to the adenosine agonist cyclohexyladenosine: evidence for a dual mechanism of action. Invest Ophthalmol Vis Sci. 2001;42(8):1837–40.

Shearer TW, Crosson CE. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2002;43(9):3016–20.

Li A, Leung CT, Peterson-Yantorno K, Stamer WD, Civan MM. Cytoskeletal dependence of adenosine triphosphate release by human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52(11):7996–8005.

Borghi V, Bastia E, Guzzetta M, Chiroli V, Toris CB, Batugo MR, et al. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocul Pharmacol Ther. 2010;26(2):125–32.

Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp Eye Res. 2011;93(3):250–5.

Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, et al. Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical models. Invest Ophthalmol Vis Sci. 2015;56(11):6558–64.

Williams RD, Novack GD, van Haarlem T, Kopczynski C. Group A-PAS. Ocular hypotensive effect of the Rho Kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152(5):834–41.e1.

Peterson JA, Tian B, McLaren JW, Hubbard WC, Geiger B, Kaufman PL. Latrunculins’ effects on intraocular pressure, aqueous humor flow, and corneal endothelium. Invest Ophthalmol Vis Sci. 2000;41(7):1749–58.

Wakatsuki T, Schwab B, Thompson NC, Elson EL. Effects of cytochalasin D and latrunculin B on mechanical properties of cells. J Cell Sci. 2001;114(Pt 5):1025–36.

Okka M, Tian B, Kaufman PL. Effect of low-dose latrunculin B on anterior segment physiologic features in the monkey eye. Arch Ophthalmol. 2004;122(10):1482–8.

Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667–77.

Roth S, Rosenbaum PS, Osinski J, Park SS, Toledano AY, Li B, et al. Ischemia induces significant changes in purine nucleoside concentration in the retina-choroid in rats. Exp Eye Res. 1997;65(6):771–9.

Agarwal R, Agarwal P. Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways. Expert Opin Ther Targets. 2014;18(5):527–39.

Mitchell CH, Carré DA, McGlinn AM, Stone RA, Civan MM. A release mechanism for stored ATP in ocular ciliary epithelial cells. Proc Natl Acad Sci USA. 1998;95(12):7174–8.

Braun JS. Ecto-5′-nucleotidase-positive cells in the choroid and ciliary body of the rat eye. Anat Rec (Hoboken). 2010;293(3):379–82.

Li A, Leung CT, Peterson-Yantorno K, Stamer WD, Mitchell CH, Civan MM. Mechanisms of ATP release by human trabecular meshwork cells, the enabling step in purinergic regulation of aqueous humor outflow. J Cell Physiol. 2012;227(1):172–82.

Li A, Zhang X, Zheng D, Ge J, Laties AM, Mitchell CH. Sustained elevation of extracellular ATP in aqueous humor from humans with primary chronic angle-closure glaucoma. Exp Eye Res. 2011;93(4):528–33.

Zhang X, Li A, Ge J, Reigada D, Laties AM, Mitchell CH. Acute increase of intraocular pressure releases ATP into the anterior chamber. Exp Eye Res. 2007;85(5):637–43.

Daines BS, Kent AR, McAleer MS, Crosson CE. Intraocular adenosine levels in normal and ocular-hypertensive patients. J Ocul Pharmacol Ther. 2003;19(2):113–9.

Zhong Y, Yang Z, Huang WC, Luo X. Adenosine, adenosine receptors and glaucoma: an updated overview. Biochim Biophys Acta. 2013;1830(4):2882–90.

Nathanson JA, McKee M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci. 1995;36(9):1774–84.

Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest Ophthalmol Vis Sci. 1995;36(9):1765–73.

Doganay S, Evereklioglu C, Turkoz Y, Er H. Decreased nitric oxide production in primary open-angle glaucoma. Eur J Ophthalmol. 2002;12(1):44–8.

Ellis DZ, Sharif NA, Dismuke WM. Endogenous regulation of human Schlemm’s canal cell volume by nitric oxide signaling. Invest Ophthalmol Vis Sci. 2010;51(11):5817–24.

Stamer WD, Lei Y, Boussommier-Calleja A, Overby DR, Ethier CR. eNOS, a pressure-dependent regulator of intraocular pressure. Invest Ophthalmol Vis Sci. 2011;52(13):9438–44.

Dismuke WM, Liang J, Overby DR, Stamer WD. Concentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility. Exp Eye Res. 2014;120:28–35.

Ashpole NE, Overby DR, Ethier CR, Stamer WD. Shear stress-triggered nitric oxide release from Schlemm’s canal cells. Invest Ophthalmol Vis Sci. 2014;55(12):8067–76.

Kotikoski H, Vapaatalo H, Oksala O. Nitric oxide and cyclic GMP enhance aqueous humor outflow facility in rabbits. Curr Eye Res. 2003;26(2):119–23.

Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389(6654):990–4.

Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4(6):446–56.

Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996;15(8):1885–93.

Feng J, Ito M, Kureishi Y, Ichikawa K, Amano M, Isaka N, et al. Rho-associated kinase of chicken gizzard smooth muscle. J Biol Chem. 1999;274(6):3744–52.

Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med (Berl). 2002;80(10):629–38.

Shimizu T, Liao JK. Rho Kinases and cardiac remodeling. Circ J. 2016;80(7):1491–8.

Goldhagen B, Proia AD, Epstein DL, Rao PV. Elevated levels of RhoA in the optic nerve head of human eyes with glaucoma. J Glaucoma. 2012;21(8):530–8.

Donegan RK, Lieberman RL. Discovery of molecular therapeutics for glaucoma: challenges, successes, and promising directions. J Med Chem. 2016;59(3):788–809.

Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho Kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42(5):1029–37.

Rosenthal R, Choritz L, Schlott S, Bechrakis NE, Jaroszewski J, Wiederholt M, et al. Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Exp Eye Res. 2005;80(6):837–45.

Fukunaga T, Ikesugi K, Nishio M, Sugimoto M, Sasoh M, Hidaka H, et al. The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading. Curr Eye Res. 2009;34(1):42–7.

Nishio M, Fukunaga T, Sugimoto M, Ikesugi K, Sumi K, Hidaka H, et al. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes. Curr Eye Res. 2009;34(4):282–6.

Henderson AJ, Hadden M, Guo C, Douglas N, Decornez H, Hellberg MR, et al. 2,3-Diaminopyrazines as Rho Kinase inhibitors. Bioorg Med Chem Lett. 2010;20(3):1137–40.

Yin Y, Cameron MD, Lin L, Khan S, Schröter T, Grant W, et al. Discovery of potent and selective urea-based ROCK inhibitors and their effects on intraocular pressure in rats. ACS Med Chem Lett. 2010;1(4):175–9.

Van de Velde S, Van Bergen T, Sijnave D, Hollanders K, Castermans K, Defert O, et al. AMA0076, a novel, locally acting Rho Kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55(2):1006–16.

Pollard TD, Cooper JA. Actin, a central player in cell shape and movement. Science. 2009;326(5957):1208–12.

Spector I, Braet F, Shochet NR, Bubb MR. New anti-actin drugs in the study of the organization and function of the actin cytoskeleton. Microsc Res Tech. 1999;47(1):18–37.

Scherlach K, Boettger D, Remme N, Hertweck C. The chemistry and biology of cytochalasans. Nat Prod Rep. 2010;27(6):869–86.

Sanka K, Maddala R, Epstein DL, Rao PV. Influence of actin cytoskeletal integrity on matrix metalloproteinase-2 activation in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2007;48(5):2105–14.

McKee CT, Wood JA, Shah NM, Fischer ME, Reilly CM, Murphy CJ, et al. The effect of biophysical attributes of the ocular trabecular meshwork associated with glaucoma on the cell response to therapeutic agents. Biomaterials. 2011;32(9):2417–23.

Peterson JA, Tian B, Geiger B, Kaufman PL. Effect of latrunculin-B on outflow facility in monkeys. Exp Eye Res. 2000;70(3):307–13.

Kim N, Crosson C, Lan T, Christian B, Brusse C, Cantone G, et al. INO-8875, an Adenosine A1 Agonist, lowers intraocular pressure through the conventional outflow pathway. Investigative Ophthalmology and Visual Science2010. p. ARVO E-Abstract 3238.

Kim N, Crosson C, Supuran T, McCauley T, Southan G, Baumgartner R, et al. INO-8875, An adenosine A1 agonist, in development for open-angle glaucoma reduces IOP in three rabbit models. Investigative Ophthalmology Visual Science2009. p. ARVO E-Abstract 4061.

Laties A, Rich CC, Stoltz R, Humbert V, Brickman C, McVicar W, et al. A randomized phase 1 dose escalation study to evaluate safety, tolerability, and pharmacokinetics of trabodenoson in healthy adult volunteers. J Ocul Pharmacol Ther. 2016;32(8):548–54.

Myers JS, Sall KN, DuBiner H, Slomowitz N, McVicar W, Rich CC, et al. A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily ocular trabodenoson in adults with ocular hypertension or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2016;32(8):555–62.

Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738–45.

Wang RF, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24(1):51–4.

Weiss M, Levy B, Kopczynski C, Van Haarlem T, Novack G. Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension. ARVO Annual Meeting Abstract2013. p. 754.

Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD. Group A-CS. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122(2):302–7.

Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD, et al. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016;100(3):339–44.

Isobe T, Mizuno K, Kaneko Y, Ohta M, Koide T, Tanabe S. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39(8):813–22.

Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, et al. Phase 1 clinical trials of a selective Rho Kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131(10):1288–95.

Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Intra-ocular pressure-lowering effects of a Rho Kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93(4):e254–60.

Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Additive intraocular pressure-lowering effects of the Rho Kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133(7):755–61.

Sato S, Hirooka K, Nitta E, Ukegawa K, Tsujikawa A. Additive intraocular pressure lowering effects of the Rho Kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33(9):1628–34.

Rasmussen CA, Kaufman PL, Ritch R, Haque R, Brazzell RK, Vittitow JL, Latrunculin B. Reduces intraocular pressure in human ocular hypertension and primary open-angle glaucoma. Transl Vis Sci Technol. 2014;3(5):1.

Wang SK, Chang RT. An emerging treatment option for glaucoma: Rho Kinase inhibitors. Clin Ophthalmol. 2014;8:883–90.

Thông tin
Thông tin xuất bản

Advances in Therapy

Tập 34

1049-1069

Thông tin tác giả